ValiRx (LSE:VAL) Change In Receivables : £-0.12 Mil (TTM As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx Change In Receivables?

ValiRx's change in receivables for the quarter that ended in Jun. 2023 was £-0.07 Mil. It means ValiRx's Accounts Receivable increased by £0.07 Mil from Dec. 2022 to Jun. 2023 .

ValiRx's change in receivables for the fiscal year that ended in Dec. 2022 was £-0.06 Mil. It means ValiRx's Accounts Receivable increased by £0.06 Mil from Dec. 2021 to Dec. 2022 .

ValiRx's Accounts Receivable for the quarter that ended in Jun. 2023 was £0.20 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. ValiRx's liquidation value for the six months ended in Jun. 2023 was £0.92 Mil.

ValiRx Change In Receivables Historical Data

The historical data trend for ValiRx's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Change In Receivables Chart

ValiRx Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-0.03

0.08

0.02

-0.01

-0.06

ValiRx Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial															0.04	-0.05	-0.01	-0.06	-0.07

ValiRx Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.12 Mil.

ValiRx (LSE:VAL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

ValiRx's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.201	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, ValiRx's accounts receivable are only considered to be worth 75% of book value:

ValiRx's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.891	-	0.12	+	0.75 * 0.201	+	0.5 * 0
=	0.92

ValiRx Change In Receivables Related Terms

Thank you for viewing the detailed overview of ValiRx's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx (LSE:VAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.